These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 428497)

  • 1. Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism.
    Schallert T; De Ryck M; Whishaw IQ; Ramirez VD; Teitelbaum P
    Exp Neurol; 1979 Apr; 64(1):33-43. PubMed ID: 428497
    [No Abstract]   [Full Text] [Related]  

  • 2. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between animal models and clinical parkinsonism.
    Marsden CD; Duvoisin RC; Jenner P; Parkes JD; Pycock C; Tarsy D
    Adv Neurol; 1975; 9():165-75. PubMed ID: 1146651
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-dopa induced increases in brain uric acid in an animal model of Parkinson's disease: a relationship to behavioral activation.
    Pinheiro-Carrera M; Tomaz C; Huston JP; Dai H; Carey RJ
    Life Sci; 1994; 55(13):991-7. PubMed ID: 8084215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
    Blume SR; Cass DK; Tseng KY
    Exp Neurol; 2009 Sep; 219(1):208-11. PubMed ID: 19460369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
    Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
    Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
    Ghorayeb I; Fernagut PO; Aubert I; Bezard E; Poewe W; Wenning GK; Tison F
    Mov Disord; 2000 May; 15(3):531-6. PubMed ID: 10830420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.
    Breese GR; Baumeister AA; McCown TJ; Emerick SG; Frye GD; Crotty K; Mueller RA
    J Pharmacol Exp Ther; 1984 Nov; 231(2):343-54. PubMed ID: 6149306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions.
    Truong L; Allbutt HN; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):91-6. PubMed ID: 19007866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
    Schneider JS; Gonczi H; Decamp E
    Brain Res; 2003 Nov; 990(1-2):38-44. PubMed ID: 14568327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.
    Fox SH; Brotchie JM
    Eur J Pharmacol; 2000 Jun; 398(1):59-64. PubMed ID: 10856448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA metabolism in cortical and striatal tissues in an animal model of parkinsonism.
    Carey RJ; Dai H; Huston JP; Pinheiro-Carrera M; Schwarting RK; Tomaz C
    Brain Res Bull; 1995; 37(3):295-9. PubMed ID: 7627573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of parkinsonism (a review).
    Klawans HL
    Dis Nerv Syst; 1968 Dec; 29(12):805-16. PubMed ID: 4388368
    [No Abstract]   [Full Text] [Related]  

  • 20. Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
    Ahmed MR; Bychkov E; Kook S; Zurkovsky L; Dalby KN; Gurevich EV
    Exp Neurol; 2015 Apr; 266():42-54. PubMed ID: 25687550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.